You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. FES-Rowing: Preventing the Secondary Conditions of Paralysis Through Vigorous Exercise

    SBC: Myolyn, LLC            Topic: NICHD

    PROJECT SUMMARY/ABSTRACT Lack of exercise is a major cause of secondary health conditions, especially for people with paralysis, for whom participation in physical activity is especially difficult. Hybrid functional electrical stimulation (H- FES) exercise enables vigorous, total body physical activity for people with paralysis. However, existing H-FES devices are neither affordable nor accessible ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Eliminating the human factor from stereotaxic surgeries

    SBC: POPNEURON LLC            Topic: 104

    Project Summary: The main goal of this research project is to develop a new line of new stereotaxic devices for small animal research that outperforms existing devices in terms of accuracy, reproducibility, and ease of use. Advancing a tool such as an electrode, injection pipette or optical fiber through a small hole in the cranium, sometimes over long distances, and placing it precisely in a part ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. STING Activators as Therapy for Cancer

    SBC: STINGINN, LLC            Topic: 101

    PROJECT SUMMARY The ability of dying cells to activate antigen presenting cells (APCs) is carefully controlled to avoid unwarranted inflammatory responses. Thus, tumor cells avoid aggravating APCs by efficiently simulating regular dying cells which following phagocytosis do not trigger inflammatory responses required for efficient cytotoxic T lymphocyte (CTL) priming. However, dying tumor cells co ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Lead compound discovery from proprietary mycobacterial strains for treatment of PTSD

    SBC: MYCOBACTERIA THERAPEUTICS CORPORATION            Topic: NCCIH

    Project Summary Immunoregulation, i.e., balanced expression of regulatory and effector T cells, is thought to be compromised in modern high-income settings due in part to reduced contact with commensal and environmentally derived bacteria, also known as “old friends”. Failed immunoregulation is thought to be one factor contributing to recent increases in stress-related and chronic inflammatory ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Novel Therapeutic Transporter to Treat Metastatic Cancers

    SBC: CYTONUS THERAPEUTICS INC            Topic: NCI

    There is critical need for therapeutic delivery devices that can be administered intravenously (IV), and effectively home to and deliver therapeutic agents to diseased tissues, while maintaining patient safety. Cytonus Therapeutics, in collaboration with UC San Diegoandapos;s Moores Cancer Center, has pioneered a unique, drug transporter system with potential to treat to a wide range of cancers in ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Commercialization of SciDAP, a next generation universal platform for collaborative data analysis

    SBC: DATIRIUM LLC            Topic: NHGRI

    Summary The recent proliferation of next-generation sequencing (NGS) - based methods for the analysis of gene expression, chromatin structure and protein-DNA interactions has created tremendous opportunities for gaining novel insights into basic biology, health, and disease. However, analysis of the resulting data requires computational expertise that many traditional biologists do not possess. He ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Chemical-based Nitric Oxide Gas-generating Drug Device for the Treatment of Pulmonary Hypertension

    SBC: Technology Commercialization Partners LLC            Topic: NHLBI

    ABSTRACT Pulmonary hypertension (PH) is a highly debilitating disease that affects about 1% of the global population, which increases up to 10% in individuals aged more than 65 years. The life expectancy for these patients is less than 10 years after diagnosis, and no specific drugs are available for pharmacologic treatment. Despite the introduction PDE5, prostacyclin analogs, and endothelin antag ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Learning from the Ebola success: Can a mAb also save lives after yellow fever infection?

    SBC: Mabloc, LLC            Topic: NIAID

    PROJECT SUMMARY/ABSTRACT The recent groundbreaking experiment using a single neutralizing monoclonal antibody (nmAb) to reduce the death rate in Ebola virus (EBOV)-infected individuals highlights the importance of this class of drug in the treatment of infectious disease. In August 2019, Dr. Anthony Fauci announced that administration of mAb114 had reduced the death rate from 70% to approximately ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Enabling self-reported outcomes for youth with developmental disabilities: The PediatricEvaluation of Disability Inventory- Patient Reported Outcome (PEDI-PRO)- Phase II

    SBC: ABLELINK TECHNOLOGIES INC            Topic: NICHD

    The lack of patient reported outcome measures (PROMs) appropriate for youth with neurodevelopmental disabilities (DD) and related cognitive impairments including Down syndrome (DS) poses a significant problem for healthcare research and practice. Parents and other professionals do not identify the same needs as youth, and failure to engage youth with DD in healthcare evaluation compromises healthc ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.

    SBC: ARCHER PHARMACEUTICALS, INC.            Topic: NIA

    Pathological hallmarks of Alzheimerandapos;s disease (AD) include extracellular deposits of Aβ peptides, intraneuronal aggregates of abnormally phosphorylated tau protein and neuroinflammation. Most proposed AD disease modifying therapies have focused on strategies that reduce brain Aβ/amyloid or tau pathological accumulation. However, such approaches have been unsuccessful in late stage AD clin ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government